# COG ACNS0332

Source: https://onco.cc/trials/acns0332/  
OnCo record `acns0332` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACNS0332 found that giving carboplatin alongside radiotherapy improved survival for children with the most aggressive group 3 medulloblastomas, while isotretinoin, tested in the same trial, did nothing and was dropped.

## Summary

ACNS0332 randomised children and young adults with high-risk medulloblastoma (metastatic, incompletely resected or with anaplasia) to 36 Gy craniospinal radiotherapy plus weekly vincristine with or without daily carboplatin as a radiosensitiser, followed by maintenance chemotherapy with or without isotretinoin. The isotretinoin randomisation closed early for futility.

Carboplatin during radiotherapy did not improve event-free survival in the whole cohort, but in the molecularly defined group 3 subgroup it improved event-free and overall survival, a finding that came from the trial's tumour profiling. The result made carboplatin radiosensitisation a standard for group 3 high-risk disease and was one of the first paediatric brain tumour trials to show benefit in a molecular subgroup.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-09-17
- Also known as: ACNS0332
- Tags: subtype-trials
- Registry id: NCT00392327
- Phase: 3
- Setting: Newly diagnosed high-risk medulloblastoma in children aged 3 to 21: craniospinal radiotherapy with weekly vincristine, with or without daily carboplatin, and with or without isotretinoin maintenance
- Sponsor: Children's Oncology Group
- Enrolled: 379
- Result: Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.

## Sources

- ClinicalTrials.gov NCT00392327: https://clinicaltrials.gov/study/NCT00392327

## Connected records

- cancers: [Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)](https://onco.cc/cancers/medulloblastoma-group-3-4/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Vincristine](https://onco.cc/drugs/vincristine/)
- people: [Sarah E. S. Leary](https://onco.cc/people/sarah-leary/)
- key papers: [ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma](https://onco.cc/key-papers/paper-acns0332-leary-jama-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/acns0332.json